1. Basic Information
Disease Overview
- Yellow Fever: Mosquito-borne flavivirus (Aedes and Haemagogus species vectors) endemic to 47 countries in sub-Saharan Africa and tropical South America. Most infections are mild or asymptomatic; roughly 15% progress to a severe "toxic phase" with jaundice, hemorrhage, and multi-organ failure. Case-fatality in the severe/toxic phase is 20–50%. WHO estimates ~200,000 cases and ~30,000 deaths annually worldwide, though true burden is likely underreported.
Recommended Use
| Population | Recommendation |
|---|---|
| Travelers ≥9 months to endemic areas | Single dose ≥10 days before travel |
| Required for IHR entry/transit | Many African and South American countries require proof of vaccination (International Certificate of Vaccination or Prophylaxis, "yellow card") for entry, especially from other endemic countries |
| Booster | WHO (2016) and CDC/ACIP concluded a single dose provides lifelong protection for most people; a booster is advised only for select groups (e.g., vaccinated during pregnancy, HIV infection, vaccinated before age 2, HSCT recipients) |
| Contraindicated | Infants <6 months, severe egg allergy (vaccine is egg-based), thymus disorder/thymectomy, symptomatic HIV or other significant immunosuppression |
Source: CDC Yellow Book; WHO Yellow Fever position paper (2013, reaffirmed 2016).
Licensed Products (U.S.)
- YF-VAX® (Sanofi) — live attenuated 17D-204 strain. Only vaccine licensed in the U.S.; administered exclusively at designated Yellow Fever Vaccination Centers.
- Stamaril® (Sanofi) — equivalent 17D-204 vaccine used outside the U.S.
2. Pre-Licensure Clinical Trial Data
The 17D strain was developed in the 1930s (Nobel Prize, 1951) and has been used in hundreds of millions of doses since. Modern licensure data rely on decades of immunogenicity studies rather than a single contemporary placebo-controlled efficacy trial, since a placebo trial would be unethical given established effectiveness and endemic disease severity.
| Metric | Data | Evidence Strength |
|---|---|---|
| Seroconversion after single dose | >90–99% by day 30 across studies | Strong |
| Durability of single-dose immunity | Neutralizing antibodies detected ≥30–40 years post-vaccination in long-term cohort studies; underpins 2016 WHO lifelong-protection policy | Strong |
| Randomized comparative safety trials | Limited; most safety data are observational/surveillance-based rather than from large modern RCTs | Limited |
Key Limitations
- No modern placebo-controlled efficacy trial: Effectiveness is inferred from immunogenicity (neutralizing antibody titers as a correlate of protection) and historical field experience, including outbreak-control campaigns, not a contemporary randomized clinical endpoint trial.
- Special-population data are sparse: Pregnant and breastfeeding people, and infants 6–8 months, are underrepresented in pre-licensure data; vaccination in these groups is generally deferred unless travel is unavoidable and risk is high.
3. Post-Licensure Safety Data
VAERS and Global Pharmacovigilance
Post-licensure surveillance since the late 1990s identified two rare but serious adverse event syndromes not apparent in earlier decades of use, prompting refined contraindications and age/risk-based precautions:
- Yellow Fever Vaccine-Associated Viscerotropic Disease (YEL-AVD): A multi-organ-failure syndrome resembling wild-type yellow fever, almost always after first-ever vaccination. Overall rate ~0.3–0.4 per 100,000 doses; substantially higher in people >60 years (~1–2.5 per 100,000) and those with thymus disorders.
- Yellow Fever Vaccine-Associated Neurologic Disease (YEL-AND): Encephalitis, Guillain-Barré syndrome, or other neurologic illness following vaccination. Rate ~0.8 per 100,000 doses overall; markedly higher in infants <9 months (historically up to several per 100,000, driving the age-6-months contraindication) and in adults >60 years.
- Anaphylaxis: Egg-based production means egg-allergic individuals are at elevated risk; skin testing/graded dosing protocols exist for those who must be vaccinated despite allergy history.
⚠ Critical Caveat
Because of YEL-AVD/YEL-AND risk being concentrated in first-time vaccinees over 60 and infants under 9 months, clinicians are advised to weigh individual destination risk against vaccine risk rather than vaccinating reflexively for any travel to an endemic country.
4. Documented Adverse Events — Evidence of Association
▶ Strong Evidence of Causal Association
- Injection site reactions, low-grade fever, headache, myalgia: Common, ~10–30% of recipients, self-limited (2–5 days). Strong
- YEL-AVD (viscerotropic disease): Rare (~0.3–0.4/100,000 doses overall; higher in first-time vaccinees >60y). Can be fatal (~60% case-fatality among confirmed cases). Strong
- YEL-AND (neurologic disease): Rare (~0.8/100,000 doses; higher in infants <9mo and adults >60y). Strong
- Anaphylaxis (egg-allergic individuals): Attributable to residual egg protein from production process. Strong
▶ Moderate or Preliminary Evidence
- Vaccination during pregnancy: Observational cohorts have not found a consistent signal for major birth defects, but data remain limited in volume; inadvertent vaccination during pregnancy is not considered an indication for termination. Limited
5. Disease Prevention Benefits
Outbreak Control Effectiveness
| Event | Outcome |
|---|---|
| Angola/DRC outbreak, 2016 | Largest urban yellow fever outbreak in decades (>7,000 suspected cases); mass vaccination campaigns (including fractional-dose strategy to stretch limited supply) brought transmission under control |
| Brazil, 2016–2019 | Sylvatic outbreak spread toward major cities; large-scale campaign vaccinated tens of millions, averting an urban re-establishment of transmission |
| Historical elimination | Mass vaccination in the mid-20th century eliminated urban (Aedes-driven) transmission from most of the Americas, though sylvatic (jungle) transmission persists |
Source: WHO Disease Outbreak News; PAHO epidemiological updates.
6. Evidence Summary
The 17D yellow fever vaccine is one of the most effective live vaccines ever developed, with a single dose providing lifelong protection for the great majority of recipients. Its main safety concern — rare but serious viscerotropic and neurologic disease, concentrated in first-time vaccinees over 60 and infants under 9 months — is well characterized and is now explicitly factored into age-based risk-benefit vaccination guidance rather than blanket recommendations.
| Domain | Evidence Grade | Key Finding |
|---|---|---|
| Immunogenicity/durability | Strong | Single dose, lifelong protection for most people |
| YEL-AVD | Strong | Rare, age- and first-dose-dependent, can be fatal |
| YEL-AND | Strong | Rare, elevated in infants <9mo and adults >60y |
| Pregnancy safety data | Limited | No consistent signal, but limited volume of data |
7. Key References
- WHO. Vaccines and vaccination against yellow fever: WHO position paper. Wkly Epidemiol Rec. 2013;88(27):269–284.
- CDC. Yellow Fever. CDC Yellow Book, Travelers’ Health. cdc.gov/yellowbook
- Staples JE, et al. Yellow Fever Vaccine: Recommendations of ACIP. MMWR Recomm Rep. 2010;59(RR-7):1–27.
- WHO. Fractional dose yellow fever vaccination as a dose-sparing strategy. who.int
- PAHO. Epidemiological Updates — Yellow Fever. paho.org